BackgroundIn medical practice, clinically unexpected measurements might be quite properly handled by the remeasurement, removal, or reclassification of patients. If these habits are not prevented during clinical research, how much of each is needed to sway an entire study?Methods and ResultsBelieving there is a difference between groups, a well-intentioned clinician researcher addresses unexpected values. We tested how much removal, remeasurement, or reclassification of patients would be needed in most cases to turn an otherwise-neutral study positive. Remeasurement of 19 patients out of 200 per group was required to make most studies positive. Removal was more powerful: just 9 out of 200 was enough. Reclassification was most powerful, with 5 out of 200 enough. The larger the study, the smaller the proportion of patients needing to be manipulated to make the study positive: the percentages needed to be remeasured, removed, or reclassified fell from 45%, 20%, and 10% respectively for a 20 patient-per-group study, to 4%, 2%, and 1% for an 800 patient-per-group study. Dot-plots, but not bar-charts, make the perhaps-inadvertent manipulations visible. Detection is possible using statistical methods such as the Tadpole test.ConclusionsBehaviours necessary for clinical practice are destructive to clinical research. Even small amounts of selective remeasurement, removal, or reclassification can produce false positive results. Size matters: larger studies are proportionately more vulnerable. If observational studies permit selective unblinded enrolment, malleable classification, or selective remeasurement, then results are not credible. Clinical research is very vulnerable to “remeasurement, removal, and reclassification”, the 3 evil R's.

The Health Statistics and Health Research Database is Estonian largest set of health-related statistics and survey results administrated by National Institute for Health Development. Use of the database is free of charge.

The database consists of eight main areas divided into sub-areas. The data tables included in the sub-areas are assigned unique codes. The data tables presented in the database can be both viewed in the Internet environment, and downloaded using different file formats (.px, .xlsx, .csv, .json). You can download the detailed database user manual here (.pdf).

The database is constantly updated with new data. Dates of updating the existing data tables and adding new data are provided in the release calendar. The date of the last update to each table is provided after the title of the table in the list of data tables.

A contact person for each sub-area is provided under the "Definitions and Methodology" link of each sub-area, so you can ask additional information about the data published in the database. Contact this person for any further questions and data requests.

Read more about publication of health statistics by National Institute for Health Development in Health Statistics Dissemination Principles.

The amount of global healthcare data is expected to increase dramatically by the year 2020. Early estimates from 2013 suggest that there were about 153 exabytes of healthcare data generated in that year. However, projections indicate that there could be as much as 2,314 exabytes of new data generated in 2020.

Clinical studies are an important part of drug development globally. The number of registered clinical trials has increased significantly recently. As of November 8, 2024, there were over 515 thousand clinical studies registered globally. The number of clinical studies has increased significantly since there were just 2,119 registered in 2000. In general, clinical trials have grown more complex in recent years and remain vital for the research and development of new drugs and products. Research and development Research and development are an important part of pharmaceutical companies and includes drug development and product development. Among all industry sectors, the pharmaceutical industry spends the largest percentage of their revenue on research and development. Many companies are active in pharmaceutical research and development globally. It is projected Swiss company Roche will remain one of the largest research and development spenders among pharmaceutical companies in the near future. Clinical studies globally Most clinical studies occurring globally are held in countries outside of the U.S. Many clinical trials performed outside the U.S. and EU are done so because it is often easier and cheaper to conduct trials in other locations. Success rates for clinical trials depend heavily on the stage of the trial and the drugs or products being developed. Recent data suggested that only around 29 percent of drugs make it from phase II to phase III.

The Clinical Data Analytics Market Report is Segmented by Deployment Model (Cloud and On-Premise), Application (Quality Improvement and Clinical Benchmarking, Clinical Decision Support, Regulatory Reporting and Compliance, Comparative Analytics/Comparative Effectiveness, and Precision Health), End-User Vertical (Payers and Providers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

In fiscal year 2023, clinical research funding by the NIH was around 18.9 billion U.S. dollars. This graph shows the actual clinical research funding by the National Institutes for Health (NIH) from FY 2013 to FY 2023 and estimates for FYs 2024 and 2025.

The clinical data analytics market revenue totaled around US$ 15,100.1 million in 2022 and is expected to reach US$ 18,769.4 million in 2023. Furthermore, with rising adoption in the healthcare industry, the overall demand for clinical data analytics is projected to record a staggering CAGR of 25.9% between 2023 and 2033, totaling a valuation of US$ 1,88,305 million by 2033.

Attribute	Key Statistics
Clinical Data Analytics Market Estimated Size (2023)	US$ 18,769.4 million
Projected Market Valuation (2033)	US$ 1,88,305.1 million
Value-based CAGR (2023 to 2033)	25.9%
Top 5 Vendor Market Share	Around 25%

Scope of Report

Attribute	Details
Estimated Market Value (2023)	US$ 18,769.4 million
Projected Market Value (2033)	US$ 1,88,305.1 million
Market CAGR 2023 to 2033	25.9%
Share of Top 5 Players	Around 25%
Forecast Period	2023 to 2033
Historical Data Available for	2018 to 2022
Market Analysis	US$ million for Value
Key Regions Covered	North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa
Key Countries Covered	United States, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Australia & New Zealand, GCC Countries, Turkey, and South Africa
Key Segments Covered	Solution, Application, End Users, and Region
Key Companies Profiled	McKesson Corporation Optum, Inc. IBM Oracle SAS Institute, Inc. IQVIA Verisk Analytics, Inc. Elsevier Medeanalytics, Inc. Truven Health Analytics, Inc. Allscripts Healthcare Solutions, Inc. Cerner Corporation Medical Information Technology Inc. Qsi Management LLC CareCloud Corporation
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Diagnosis data of patients and patients in hospitals.

The hospital diagnosis statistics are part of the hospital statistics and have been collected annually from all hospitals since 1993. The statistics include information on the main diagnosis (coded according to ICD-10), length of stay, department and selected sociodemographic characteristics such as age, gender and place of residence, among others.

Basic data of hospitals and preventive care or rehabilitation facilities.

The basic data statistics are part of the hospital statistics. The material and personnel resources of hospitals and preventive or rehabilitation facilities and their specialist departments have been reported annually since 1990.

The aggregated data are freely accessible.

This statistic shows the size of the global big data analytics services market related to healthcare in 2016 and a forecast for 2025, by application. It is predicted that by 2025 the market for health-related financial analytics services using big data will increase to over 13 billion U.S. dollars.

This statistic shows the number of registered clinical studies worldwide by location, as of November 8, 2024. The number of registered clinical studies in non-U.S. areas was at around 284 thousand, while in the U.S. the number was at around 154 thousand.

Data from previous studies examining patient-related risk factors for aseptic loosening in patients who have undergone hip and knee arthroplasty.

Modern Bayesian statistics in clinical research is a book. It was written by Ton J. M. Cleophas and published by : Springer in 2018.

PRISMA Checklist. (DOC)

The global clinical data management systems market size was valued at USD 1,837.50 million in 2023 and it is expected to grow to USD 4,490.53 million by 2031 at a CAGR of 13.6%.

The Clinical Data Analytics in Healthcare market is rapidly evolving, serving as a crucial component in enhancing the quality of patient care and optimizing operational efficiencies within healthcare organizations. As healthcare systems increasingly rely on data-driven decision-making processes, the demand for sophi

Statistical reports from all medical institutions in Latvia according to their medical activity (ambulatory and inpatient work, medical staff, radiology, dentistry, abortions, medical tourism, emergency medical assistance, etc.)

Quality scoring components for 8 clinical trials included.

This dataset is about books and is filtered where the author includes Ton J. M. Cleophas and the book includes Modern Bayesian statistics in clinical research, featuring 7 columns including author, BNB id, book, book publisher, and ISBN. The preview is ordered by publication date (descending).

This statistic shows the size of the global big data market related to healthcare in 2016 and a forecast for 2025. It is estimated that over this period the market will increase from around 11.5 billion to nearly 70 billion U.S. dollars.

Statistical Analysis Software Market size was valued at USD 7,963.44 Million in 2023 and is projected to reach USD 13,023.63 Million by 2030, growing at a CAGR of 7.28% during the forecast period 2024-2030.

Global Statistical Analysis Software Market Drivers

The market drivers for the Statistical Analysis Software Market can be influenced by various factors. These may include:

Growing Data Complexity and Volume: The demand for sophisticated statistical analysis tools has been fueled by the exponential rise in data volume and complexity across a range of industries. Robust software solutions are necessary for organizations to evaluate and extract significant insights from huge datasets.
Growing Adoption of Data-Driven Decision-Making: Businesses are adopting a data-driven approach to decision-making at a faster rate. Utilizing statistical analysis tools, companies can extract meaningful insights from data to improve operational effectiveness and strategic planning.
Developments in Analytics and Machine Learning: As these fields continue to progress, statistical analysis software is now capable of more. These tools’ increasing popularity can be attributed to features like sophisticated modeling and predictive analytics.
A greater emphasis is being placed on business intelligence: Analytics and business intelligence are now essential components of corporate strategy. In order to provide business intelligence tools for studying trends, patterns, and performance measures, statistical analysis software is essential.
Increasing Need in Life Sciences and Healthcare: Large volumes of data are produced by the life sciences and healthcare sectors, necessitating complex statistical analysis. The need for data-driven insights in clinical trials, medical research, and healthcare administration is driving the market for statistical analysis software.
Growth of Retail and E-Commerce: The retail and e-commerce industries use statistical analytic tools for inventory optimization, demand forecasting, and customer behavior analysis. The need for analytics tools is fueled in part by the expansion of online retail and data-driven marketing techniques.
Government Regulations and Initiatives: Statistical analysis is frequently required for regulatory reporting and compliance with government initiatives, particularly in the healthcare and finance sectors. In these regulated industries, statistical analysis software uptake is driven by this.
Big Data Analytics’s Emergence: As big data analytics has grown in popularity, there has been a demand for advanced tools that can handle and analyze enormous datasets effectively. Software for statistical analysis is essential for deriving valuable conclusions from large amounts of data.
Demand for Real-Time Analytics: In order to make deft judgments fast, there is a growing need for real-time analytics. Many different businesses have a significant demand for statistical analysis software that provides real-time data processing and analysis capabilities.
Growing Awareness and Education: As more people become aware of the advantages of using statistical analysis in decision-making, its use has expanded across a range of academic and research institutions. The market for statistical analysis software is influenced by the academic sector.
Trends in Remote Work: As more people around the world work from home, they are depending more on digital tools and analytics to collaborate and make decisions. Software for statistical analysis makes it possible for distant teams to efficiently examine data and exchange findings.